CD24 and neoplasm: Preclinical studies have demonstrated that CD24 promotes immune evasion in ovarian cancer and triple-negative breast cancer by interacting with the inhibitory receptor sialic acid binding ig-like lectin 10 (Siglec-10) expressed by tumor-associated macrophages (TAMs).